109 related articles for article (PubMed ID: 22587593)
1. Decreased GAD(65)-specific Th1/Tc1 phenotype in children with Type 1 diabetes treated with GAD-alum.
Axelsson S; Hjorth M; Ludvigsson J; Casas R
Diabet Med; 2012 Oct; 29(10):1272-8. PubMed ID: 22587593
[TBL] [Abstract][Full Text] [Related]
2. Long-lasting immune responses 4 years after GAD-alum treatment in children with type 1 diabetes.
Axelsson S; Chéramy M; Hjorth M; Pihl M; Akerman L; Martinuzzi E; Mallone R; Ludvigsson J; Casas R
PLoS One; 2011; 6(12):e29008. PubMed ID: 22174945
[TBL] [Abstract][Full Text] [Related]
3. Impaired CD4 and CD8 T cell phenotype and reduced chemokine secretion in recent-onset type 1 diabetic children.
Hedman M; Faresjö M; Axelsson S; Ludvigsson J; Casas R
Clin Exp Immunol; 2008 Sep; 153(3):360-8. PubMed ID: 18803760
[TBL] [Abstract][Full Text] [Related]
4. Switch from a dominant Th1-associated immune profile during the pre-diabetic phase in favour of a temporary increase of a Th3-associated and inflammatory immune profile at the onset of type 1 diabetes.
Ryden A; Stechova K; Durilova M; Faresjö M
Diabetes Metab Res Rev; 2009 May; 25(4):335-43. PubMed ID: 19382103
[TBL] [Abstract][Full Text] [Related]
5. GAD-alum treatment induces GAD65-specific CD4+CD25highFOXP3+ cells in type 1 diabetic patients.
Hjorth M; Axelsson S; Rydén A; Faresjö M; Ludvigsson J; Casas R
Clin Immunol; 2011 Jan; 138(1):117-26. PubMed ID: 21044870
[TBL] [Abstract][Full Text] [Related]
6. Early induction of GAD(65)-reactive Th2 response in type 1 diabetic children treated with alum-formulated GAD(65).
Axelsson S; Hjorth M; Akerman L; Ludvigsson J; Casas R
Diabetes Metab Res Rev; 2010 Oct; 26(7):559-68. PubMed ID: 20830731
[TBL] [Abstract][Full Text] [Related]
7. Regulatory T cell phenotype and function 4 years after GAD-alum treatment in children with type 1 diabetes.
Pihl M; Akerman L; Axelsson S; Chéramy M; Hjorth M; Mallone R; Ludvigsson J; Casas R
Clin Exp Immunol; 2013 Jun; 172(3):394-402. PubMed ID: 23600827
[TBL] [Abstract][Full Text] [Related]
8. GAD-alum immunotherapy in type 1 diabetes expands bifunctional Th1/Th2 autoreactive CD4 T cells.
Arif S; Gomez-Tourino I; Kamra Y; Pujol-Autonell I; Hanton E; Tree T; Melandri D; Hull C; Wherrett DK; Beam C; Roep BO; Lorenc A; Peakman M
Diabetologia; 2020 Jun; 63(6):1186-1198. PubMed ID: 32248243
[TBL] [Abstract][Full Text] [Related]
9. GAD-specific T cells are induced by GAD-alum treatment in Type-1 diabetes patients.
Pihl M; Barcenilla H; Axelsson S; Chéramy M; Åkerman L; Johansson I; Ludvigsson J; Casas R
Clin Immunol; 2017 Mar; 176():114-121. PubMed ID: 28131926
[TBL] [Abstract][Full Text] [Related]
10. IFN-gamma and IL-12 differentially regulate CC-chemokine secretion and CCR5 expression in human T lymphocytes.
Losana G; Bovolenta C; Rigamonti L; Borghi I; Altare F; Jouanguy E; Forni G; Casanova JL; Sherry B; Mengozzi M; Trinchieri G; Poli G; Gerosa F; Novelli F
J Leukoc Biol; 2002 Oct; 72(4):735-42. PubMed ID: 12377943
[TBL] [Abstract][Full Text] [Related]
11. GAD-alum immunotherapy in Type 1 diabetes mellitus.
Morales AE; Thrailkill KM
Immunotherapy; 2011 Mar; 3(3):323-32. PubMed ID: 21395375
[TBL] [Abstract][Full Text] [Related]
12. GAD65 antigen therapy in recently diagnosed type 1 diabetes mellitus.
Ludvigsson J; Krisky D; Casas R; Battelino T; Castaño L; Greening J; Kordonouri O; Otonkoski T; Pozzilli P; Robert JJ; Veeze HJ; Palmer J; Samuelsson U; Elding Larsson H; Åman J; Kärdell G; Neiderud Helsingborg J; Lundström G; Albinsson E; Carlsson A; Nordvall M; Fors H; Arvidsson CG; Edvardson S; Hanås R; Larsson K; Rathsman B; Forsgren H; Desaix H; Forsander G; Nilsson NÖ; Åkesson CG; Keskinen P; Veijola R; Talvitie T; Raile K; Kapellen T; Burger W; Neu A; Engelsberger I; Heidtmann B; Bechtold S; Leslie D; Chiarelli F; Cicognani A; Chiumello G; Cerutti F; Zuccotti GV; Gomez Gila A; Rica I; Barrio R; Clemente M; López Garcia MJ; Rodriguez M; Gonzalez I; Lopez JP; Oyarzabal M; Reeser HM; Nuboer R; Stouthart P; Bratina N; Bratanic N; de Kerdanet M; Weill J; Ser N; Barat P; Bertrand AM; Carel JC; Reynaud R; Coutant R; Baron S
N Engl J Med; 2012 Feb; 366(5):433-42. PubMed ID: 22296077
[TBL] [Abstract][Full Text] [Related]
13. CD8+ T lymphocytes specific for glutamic acid decarboxylase 90-98 epitope mediate diabetes in NOD SCID mouse.
Sévère S; Gauvrit A; Vu AT; Bach JM
Mol Immunol; 2007 Apr; 44(11):2950-60. PubMed ID: 17336387
[TBL] [Abstract][Full Text] [Related]
14. Differential expression of the chemokine receptors by the Th1- and Th2-type effector populations within circulating CD4+ T cells.
Yamamoto J; Adachi Y; Onoue Y; Adachi YS; Okabe Y; Itazawa T; Toyoda M; Seki T; Morohashi M; Matsushima K; Miyawaki T
J Leukoc Biol; 2000 Oct; 68(4):568-74. PubMed ID: 11037980
[TBL] [Abstract][Full Text] [Related]
15. High T-helper-1 cytokines but low T-helper-3 cytokines, inflammatory cytokines and chemokines in children with high risk of developing type 1 diabetes.
Stechova K; Bohmova K; Vrabelova Z; Sepa A; Stadlerova G; Zacharovova K; Faresjö M
Diabetes Metab Res Rev; 2007 Sep; 23(6):462-71. PubMed ID: 17315139
[TBL] [Abstract][Full Text] [Related]
16. Diminished IFN-gamma response to diabetes-associated autoantigens in children at diagnosis and during follow up of type 1 diabetes.
Faresjö MK; Vaarala O; Thuswaldner S; Ilonen J; Hinkkanen A; Ludvigsson J
Diabetes Metab Res Rev; 2006; 22(6):462-70. PubMed ID: 16572494
[TBL] [Abstract][Full Text] [Related]
17. Expression of TH1/TH2-related chemokine receptors on peripheral T cells and correlation with clinical disease activity in patients with multiple sclerosis.
Nakajima H; Fukuda K; Doi Y; Sugino M; Kimura F; Hanafusa T; Ikemoto T; Shimizu A
Eur Neurol; 2004; 52(3):162-8. PubMed ID: 15528917
[TBL] [Abstract][Full Text] [Related]
18. Dynamic T-lymphocyte chemokine receptor expression induced by interferon-beta therapy in multiple sclerosis.
Krakauer M; Sorensen PS; Khademi M; Olsson T; Sellebjerg F
Scand J Immunol; 2006 Aug; 64(2):155-63. PubMed ID: 16867161
[TBL] [Abstract][Full Text] [Related]
19. Nonantigen specific CD8+ T suppressor lymphocytes originate from CD8+CD28- T cells and inhibit both T-cell proliferation and CTL function.
Filaci G; Fravega M; Negrini S; Procopio F; Fenoglio D; Rizzi M; Brenci S; Contini P; Olive D; Ghio M; Setti M; Accolla RS; Puppo F; Indiveri F
Hum Immunol; 2004 Feb; 65(2):142-56. PubMed ID: 14969769
[TBL] [Abstract][Full Text] [Related]
20. Extended evaluation of the safety and efficacy of GAD treatment of children and adolescents with recent-onset type 1 diabetes: a randomised controlled trial.
Ludvigsson J; Hjorth M; Chéramy M; Axelsson S; Pihl M; Forsander G; Nilsson NÖ; Samuelsson BO; Wood T; Aman J; Ortqvist E; Casas R
Diabetologia; 2011 Mar; 54(3):634-40. PubMed ID: 21116604
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
